AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TRDA · NASDAQ · Biotechnology

Entrada Therapeutics (TRDA)

Applies a cyclic-peptide delivery platform to exon-skipping therapies for Duchenne muscular dystrophy and myotonic dystrophy.

$6.41

vs last close−0.30 (−4.47%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	44	42	59	95	20	37	21	2	2	1	1	1
Cost of revenue	22	0	0	0	0	0	0	0	38	1	1	0
Gross profit	22	42	59	95	20	37	21	2	−37	0	0	1
	8	37	38	41	41	43	42	49	10	43	42	46
Research & development	22	28	29	32	31	33	32	38	38	34	33	35
	8	9	9	9	10	10	10	11	10	10	10	10
General & administrative	8	9	9	9	10	10	10	11	10	10	10	10
Other expenses	−22	0	0	0	0	0	0	0	−38	−1	−1	0
Operating income	14	5	21	53	−22	−6	−22	−47	−47	−42	−42	−45
	39	4	4	4	6	5	4	4	4	3	3	2
Interest income	4	4	4	4	6	5	4	4	4	3	3	2
Other non-operating income	0	−4	−4	−4	−6	−5	−4	−4	−4	−3	−3	−2
Income before tax	53	9	25	58	−16	−1	−17	−43	−43	−39	−40	−43
Income tax expense	17	19	2	3	−2	−2	0	0	1	0	0	0
Net income from continuing operations	35	−10	23	55	−14	1	−17	−43	−44	−39	−40	−43
Net income	35	−10	23	55	−14	1	−17	−43	−44	−39	−40	−43
EPS, basic	$1.07	−$0.29	$0.70	$1.61	−$0.35	$0.03	−$0.42	−$1.04	−$1.06	−$0.95	−$0.95	−$1.01
EPS, diluted	$1.02	−$0.29	$0.68	$1.55	−$0.35	$0.03	−$0.42	−$1.04	−$1.06	−$0.95	−$0.95	−$1.01
Weighted average shares, basic	33	33	33	34	41	41	41	41	41	41	42	42
Weighted average shares, diluted	35	33	35	36	41	43	41	41	41	41	42	42
EBITDA	15	10	26	59	−15	0	−16	−42	−42	−42	−39	−42
Depreciation & amortization	1	1	1	1	1	1	1	1	1	−3	1	1
EBIT	14	9	25	58	−16	−1	−17	−43	−43	−39	−40	−43